PT - JOURNAL ARTICLE AU - Moksnes, Marta R AU - Røsjø, Helge AU - Richmond, Anne AU - Lyngbakken, Magnus N AU - Graham, Sarah E AU - Hansen, Ailin Falkmo AU - Wolford, Brooke N AU - Taliun, Sarah A Gagliano AU - LeFaive, Jonathon AU - Rasheed, Humaira AU - Thomas, Laurent F AU - Zhou, Wei AU - Aung, Nay AU - Surakka, Ida AU - Douville, Nicholas J AU - Campbell, Archie AU - Porteous, David J AU - Petersen, Steffen E. AU - Munroe, Patricia B. AU - Welsh, Paul AU - Sattar, Naveed AU - Smith, George Davey AU - Fritsche, Lars G AU - Nielsen, Jonas B AU - Åsvold, Bjørn Olav AU - Hveem, Kristian AU - Hayward, Caroline AU - Willer, Cristen J AU - Brumpton, Ben M AU - Omland, Torbjørn TI - Using human genetics to understand the causes and consequences of circulating cardiac troponin I in the general population AID - 10.1101/2020.09.04.20187401 DP - 2020 Jan 01 TA - medRxiv PG - 2020.09.04.20187401 4099 - http://medrxiv.org/content/early/2020/12/04/2020.09.04.20187401.short 4100 - http://medrxiv.org/content/early/2020/12/04/2020.09.04.20187401.full AB - Circulating cardiac troponin proteins are associated with structural heart disease and predict incident cardiovascular disease in the general population. However, the genetic contribution to cardiac troponin I (cTnI) concentrations and its causal effect on cardiovascular phenotypes is unclear. We combine data from two large population-based studies, the Trøndelag Health Study and the Generation Scotland Scottish Family Health Study and perform a genome-wide association study of high-sensitivity cTnI concentrations with 48 115 individuals. We further used two-sample Mendelian randomization to investigate the causal effects of circulating cTnI on acute myocardial infarction and heart failure.We identified 12 genetic loci (8 novel) associated with cTnI concentrations. Associated protein-altering variants highlighted putative functional genes: CAND2, HABP2, ANO5, APOH, FHOD3, TNFAIP2, KLKB1 and LMAN1. Phenome-wide association tests in 1283 phecodes and 274 continuous traits in UK Biobank showed associations between a polygenic risk score for cTnI and cardiac arrhythmias, aspartate aminotransferase 1 and anthropometric measures. Excluding individuals with a known history of comorbidities did not materially change associations with cTnI. Using two-sample Mendelian randomization we confirmed the non-causal role of cTnI in acute myocardial infarction (5 948 cases, 355 246 controls). We found some indications for a causal role of cTnI in heart failure (47 309 cases and 930 014 controls), but this was not supported by secondary analyses using left ventricular mass as outcome (18 257 individuals).Our findings clarify the biology underlying the heritable contribution to circulating cTnI and support cTnI as a non-causal biomarker for acute myocardial infarction and heart failure development in the general population. Using genetically informed methods for causal inference of cTnI helps inform the role and value of measuring cTnI in the general population.Competing Interest StatementTO reports research support and honoraria from Abbott Diagnostics and Roche Diagnostics and honoraria from Siemens Healthineers, manufacturers of high sensitivity cardiac troponin assays. The other authors declare no competing interests.Funding StatementThe genotyping in HUNT was financed by the National Institutes of Health, University of Michigan, the Research Council of Norway, the Liaison Committee for Education, Research and Innovation in Central Norway, and the Joint Research Committee between St Olav's hospital and the Faculty of Medicine and Health Sciences, NTNU. The cardiac troponin I analyses in HUNT were sponsored by Abbott Diagnostics.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Participation in HUNT is based on informed consent, and the study has been approved by the Norwegian Data Protection Authority and the Regional Committee for Medical and Health Research Ethics in Central Norway (REK Reference number: 2015/2294). The GS:SFHS obtained written informed consent from all participants and received ethical approval from the National Health Service Tayside Committee on Medical Research Ethics (REC Reference number: 05/S1401/89). This study was covered by the ethics approval for UK Biobank studies (application 24460) from the NHS National Research Ethics Service on 17th June 2011 (Ref 11/NW/0382) and extended on 10th May 2016 (Ref 16/NW/0274).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData generated or analyzed during this study are available from the corresponding authors upon reasonable request.